REGULATORY
FDA De Novo granted
QIKcap System, DEN250004, establishing a new device classification.
BUSINESS MODEL
$89 / bed / month
Subscription includes one device per bed and caps.
INTELLECTUAL PROPERTY
Patented portfolio
U.S. patents issued across UV-C sterilization and multiport delivery, most recently U.S. 12,714,760 (August 2026).
PIPELINE
Platform products
QIKswab now offered; MDD in development.
Why now
A large, measurable problem with a clear buyer.
Hospital-acquired bloodstream infections carry penalties under CMS's HAC Reduction Program, and hospitals adopt infection prevention tools through value analysis committees. QIKcap is priced per bed per month to fit that process.
Connect with our team
For accredited investors and strategic partners.
This page is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Statements about future plans are forward-looking and subject to risks and uncertainties.
Partner with HAIS
HAIS is commercializing the QIKcap System, an FDA De Novo–granted UV-C device for needleless connectors, with ISO 13485 certification in place and manufacturing ramp-up underway.
We welcome accredited investors and strategic partners in vascular access and infection prevention. This page is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities.
Highlights
• Regulatory: FDA De Novo grant for the QIKcap System (DEN250004).
• Team: Supported by experienced advisors in medtech, regulatory affairs and infection prevention.
• Business model: Per-bed subscription designed for scalable adoption and recurring revenue.
• Milestones: ISO 13485 certification, Series A closed and manufacturing ramp-up underway.
• Growth: Raising capital to scale commercialization and partnerships, including non-dilutive funding.
• Intellectual property: Patented portfolio across UV-C sterilization and multiport delivery.